NeurAegis, Inc. is a late preclinical stage neuropharmaceutical company pioneering the development of breakthrough treatments for neurological disorders including traumatic brain injury (TBI)/concussion and epilepsy. Firm's initial focus is developing first-in-class, novel protease inhibitors for TBI where there are currently no FDA approved treatments.
